Similar articles

• [Adjuvant chemotherapy for pancreatic cancer].

  Takeda S, Nakao A. Takeda S, et al. Nihon Rinsho. 2006 Jan;64 Suppl 1:215-8. Nihon Rinsho. 2006. PMID: 16457253 Review. Japanese. No abstract available.
• [Chemoradiation therapy and immunotherapy for pancreatic cancer].

  Egawa S, Motoi F, Fukuyama S, Sunamura M, Unno M. Egawa S, et al. Nihon Rinsho. 2006 Jan;64 Suppl 1:258-63. Nihon Rinsho. 2006. PMID: 16457262 Review. Japanese. No abstract available.
• [Management of pancreatic cancer: current therapy and continued development].

  Tsukada K, Nagata T, Yoshino T. Tsukada K, et al. Nihon Rinsho. 2006 Jan;64 Suppl 1:175-9. Nihon Rinsho. 2006. PMID: 16457244 Review. Japanese. No abstract available.
• [Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].

  Lluís F. Lluís F. Gastroenterol Hepatol. 2009 Feb;32(2):120-1. doi: 10.1016/j.gastrohep.2008.10.003. Epub 2009 Feb 5. Gastroenterol Hepatol. 2009. PMID: 19231687 Spanish. No abstract available.
• Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.

  Okabayashi T, Nishimori I, Nishioka A, Yamashita K, Sugimoto T, Dabanaka K, Maeda H, Kohsaki T, Ogawa Y, Kobayashi M, Onishi S, Hanazaki K. Okabayashi T, et al. Oncol Rep. 2008 Sep;20(3):651-6. Oncol Rep. 2008. PMID: 18695919